查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
美國的醫藥品無菌測試市場:規模，佔有率，趨勢分析報告:各類型，各實驗類型，各最終用途，樣品，各市場區隔預測(2022年～2030年)
市場調查報告書
商品編碼
1170898

美國的醫藥品無菌測試市場:規模，佔有率，趨勢分析報告:各類型，各實驗類型，各最終用途，樣品，各市場區隔預測(2022年～2030年)

U.S. Pharmaceutical Sterility Testing Market Size, Share & Trends Analysis Report By Type (In-house, Outsourcing), By Test Type, By End-use, By Sample (Sterile Drugs, Biologics & Therapeutics), And Segment Forecasts, 2022 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

美國的醫藥品無菌實驗的市場規模在2022年～2030年的預測期間內預計將以10.9％的年複合成長率擴大，到2030年前將達到11億8,000萬美元。

政府支持的醫療保健行業投資、研發活動的增加以及國內對新治療藥物不斷增長的需求是增長的主要驅動力。

本報告提供美國的醫藥品無菌測試市場的相關調查，提供市場現狀，以及各類型，各實驗類型，各最終用途，樣品，各市場區隔趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 調查手法和範圍

第2章 摘要整理

第3章 美國的醫藥品無菌測試市場的變數，趨勢，範圍

  • 市場系列預測
  • 滲透與成長預測的製圖
  • 市場動態
  • 美國的醫藥品無菌測試市場分析工具
    • 波特的五力分析
    • 大環境分析
    • 主要交易和策略性聯盟分析
    • COVID-19影響與改革策略

第4章 美國的醫藥品無菌測試市場:各類型估計·趨勢分析

  • 定義和範圍
  • 美國的醫藥品無菌測試市場佔有率，2021年及2030年
    • 公司內部的醫藥品無菌實驗
    • 外包的醫藥品無菌實驗

第5章 美國的醫藥品無菌測試市場:各產品類型估計·趨勢分析

  • 定義和範圍
  • 美國的醫藥品無菌測試市場佔有率，2021年及2030年
    • 套件和試劑
    • 設備
    • 服務

第6章 美國的醫藥品無菌測試市場:各實驗類型估計·趨勢分析

  • 定義和範圍
  • 美國的醫藥品無菌測試市場佔有率，2021年及2030年
    • 無菌實驗
    • 微生物附著量實驗
    • 細菌終局毒素實驗

第7章 美國的醫藥品無菌測試市場:樣品估計·趨勢分析

  • 定義和範圍
  • 美國的醫藥品無菌測試市場佔有率，2021年及2030年
    • 醫藥品
    • 醫療設備
    • 生物醫藥品

第8章 美國的醫藥品無菌測試市場:各最終用途估計·趨勢分析

  • 定義和範圍
  • 美國的醫藥品無菌測試市場佔有率，2021年及2030年
    • 調劑藥局
    • 醫療設備廠商
    • 製藥公司
    • 其他

第9章 競爭分析

  • 主要市場參與企業的最近的開發與影響分析
  • 企業/競爭的分類(主要創新者，市場領導者，新興企業)
  • 參加者的分類
    • 創新者
      • STERIS
      • Boston Analytical
      • Charles River Laboratories
      • SGS SA
  • 業者情勢
    • 主要的服務供應商的清單
    • 市場差異化要素
    • 美國的醫藥品無菌測試市場佔有率分析

第10章 競爭情形

  • 企業簡介
    • SGS SA
    • Laboratory Corporation of America Holdings
    • Boston Analytical
    • Charles River Laboratories
    • Pacific Biolabs
    • STERIS
    • Pace Analytical
    • Nelson Laboratories, LLC
    • Infinity Laboratories
    • Thermo Fisher Scientific, Inc.
Product Code: GVR-2-68038-403-1

U.S. Pharmaceutical Sterility Testing Market Growth & Trends:

The U.S. pharmaceutical sterility testing market size is anticipated to reach USD 1.18 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 10.9% from 2022 to 2030. Supportive government investment in the healthcare industry, increasing R&D activities, and growing demand for new therapeutics in the country are the key factors driving the growth. The majority of clinical trials worldwide are performed in the U.S. alone.

According to ClinicalTrials.gov, as of October 2022, over 31% of global clinical trials were registered in the U.S. alone. This is due to the significant number of initiatives taken by public organizations in the country to support R&D activities. The presence of technologically advanced infrastructure and an increase in R&D investment by pharmaceutical companies are also supporting clinical trials in the country. This is expected to improve the number of new medications and medical devices in the coming years in the U.S. and support the market in the post-pandemic period.

The government is keen on bringing down healthcare costs, which is anticipated to encourage the U.S. Food and Drug Administration (FDA) to promote the fast approval of generic pharmaceuticals. Faster approvals drive the need for newer sterility testing methods. This is anticipated to encourage market participants to spend more on sterility solutions and, in turn, expand the market. With an increasing demand for drugs, companies are launching new drugs with different routes of administration, dosage, and indication. These launches require thorough sterility testing and, thus, are anticipated to drive the industry's growth.

The majority of pharmaceutical companies, biopharmaceutical companies, CROs, and CMOs are headquartered in the U.S. Companies such as Catalent, Inc., Pfizer Inc., AbbVie, Merck; Co. Johnson & Johnson, and Abbott are located in the U.S. The high number of pharmaceutical companies, biopharmaceutical companies, CMOs, and CROs located in the U.S. contributes to the high demand for sterility testing of pharmaceuticals, thus supporting the market growth.

The country suffers from a high burden of cancer. Due to this, government-based research institutes in the U.S. are constantly trying to improve cancer research funding in the country. For instance, in May 2022, the American Institute of Cancer Research stated that it had funded more than USD 110 million in cancer research in 2022, and it intends to fund more in the coming years to reduce the burden of cancer. Such initiatives are expected to increase the number of new medications for cancer in the coming years, thus increasing the demand for sterility testing of cancer drugs in the post-pandemic period.

U.S. Pharmaceutical Sterility Testing Market Report Highlights:

  • Outsourcing emerged as the largest segment in 2021 with a share of 45.2%, as pharmaceutical and biopharmaceutical companies are trying to reduce expenses and hence outsourcing non-core functions such as sterility testing
  • The sterility testing segment, by test type is expected to witness the fastest CAGR of 11.3% across the forecast as these tests are recommended by regulatory authorities such as the USFDA
  • Based on product type, the kits and reagents segment held the largest share of 59.7% in 2021, due to the high consumption of these products in sterility testing
  • The biopharmaceuticals segment by the sample is expected to grow at the fastest rate of 11.2% CAGR across the forecast owing to the growing demand for biologics such as vaccines, and monoclonal antibodies in the country for treating chronic and infectious diseases
  • Based on end-use, the pharmaceutical companies accounted for the largest share of 42.9% in 2021, owing to the growing number of drug recalls due to lack of sterility, thus supporting segment growth

Table of Contents

Chapter 1 Methodology And Scope

  • 1.1.Market Segmentation & Scope
    • 1.1.1.Type
    • 1.1.2.Product Type
    • 1.1.3.Test Type
    • 1.1.4.Sample
    • 1.1.5.End-Use
    • 1.1.6.Regional Scope
    • 1.1.7.Estimates And Forecast Timeline
  • 1.2.Research Methodology
  • 1.3.Information Procurement
    • 1.3.1.Purchased Database
    • 1.3.2.GVR's Internal Database
    • 1.3.3.Secondary Sources
    • 1.3.4.Primary Research
    • 1.3.5.Details Of Primary Research
  • 1.4.Information Or Data Analysis
    • 1.4.1.Data Analysis Models
  • 1.5.Market Formulation & Validation
  • 1.6.Model Details
    • 1.6.1.Commodity Flow Analysis (Model 1)
    • 1.6.1.1.Approach 1: Commodity Flow Approach
    • 1.6.2.Volume Price Analysis (Model 2)
    • 1.6.2.1.Approach 2: Volume Price Analysis
  • 1.7.List Of Secondary Sources
  • 1.8.List Of Primary Sources
  • 1.9.Objectives
    • 1.9.1.Objective 1
    • 1.9.2.Objective 2

Chapter 2 Executive Summary

  • 2.1.Market Outlook

Chapter 3 U.S. Pharmaceutical Sterility Testing Market Variables, Trends & Scope

  • 3.1.Market Lineage Outlook
    • 3.1.1.Parent Market Outlook
    • 3.1.2.Related/Ancillary Market Outlook
  • 3.2.Penetration & Growth Prospect Mapping
  • 3.3.Market Dynamics
    • 3.3.1.Market Driver Analysis
      • 3.3.1.1.Supportive Government Investment In The Healthcare Industry
      • 3.3.1.2.Increasing R&D Activities
      • 3.3.1.3.Increasing Number Of Drug Launches
      • 3.3.1.4.Increasing Focus On Quality And Sterility
    • 3.3.2.Market Restraint Analysis
      • 3.3.2.1.Third-Party Performance
  • 3.4.U.S. Pharmaceutical Sterility Testing Market Analysis Tools
    • 3.4.1.Porter's Five Forces Analysis
    • 3.4.2.PESTLE Analysis
    • 3.4.3.Major Deals & Strategic Alliances Analysis
      • 3.4.3.1.Mergers And Acquisition
      • 3.4.3.2.Expansions
      • 3.4.3.3.Agreements And Collaborations
      • 3.4.3.4.Product And Service Launches
    • 3.5.Covid-19 Impact And Reformation Strategy

Chapter 4 U.S. Pharmaceutical Sterility Testing Market: Type Estimates & Trend Analysis

  • 4.1.Definitions And Scope
  • 4.2.U.S. Pharmaceutical Sterility Testing Market Share, 2021 & 2030
    • 4.2.1.In-House Pharmaceutical Sterility Testing
      • 4.2.1.1.In-House Pharmaceutical Sterility Testing Market Estimates And Forecast 2018 - 2030 (USD Million)
    • 4.2.2.Outsourcing Pharmaceutical Sterility Testing
      • 4.2.2.1.Outsourcing Pharmaceutical Sterility Testing Market Estimates And Forecast 2018 - 2030 (USD Million)

Chapter 5 U.S. Pharmaceutical Sterility Testing Market: Product Type Estimates & Trend Analysis

  • 5.1.Definitions And Scope
  • 5.2.U.S. Pharmaceutical Sterility Testing Market Share, 2021 & 2030
    • 5.2.1.Kits And Reagents
      • 5.2.1.1.Kits And Reagents Market Estimates And Forecast 2018 - 2030 (USD Million)
    • 5.2.2.Instruments
      • 5.2.2.1.Instruments Market Estimates And Forecast 2018 - 2030 (USD Million)
    • 5.2.3.Service
      • 5.2.3.1.Service Market Estimates And Forecast 2018 - 2030 (USD Million)

Chapter 6 U.S. Pharmaceutical Sterility Testing Market: Test Type Estimates & Trend Analysis

  • 6.1.Definitions And Scope
  • 6.2. U.S. Pharmaceutical Sterility Testing Market Share, 2021 & 2030
    • 6.2.1.Sterility Testing
      • 6.2.1.1.Sterility Testing Market Estimates And Forecast 2018 - 2030 (USD Million)
      • 6.2.1.2.Membrane Filtration
        • 6.2.1.2.1.Membrane Filtration Market Estimates And Forecast 2018 - 2030 (USD Million)
      • 6.2.1.3.Direct Inoculation
        • 6.2.1.3.1.Direct Inoculation Market Estimates And Forecast 2018 - 2030 (USD Million)
      • 6.2.1.4.Product Flush
        • 6.2.1.4.1.Product Flush Market Estimates And Forecast 2018 - 2030 (USD Million)
    • 6.2.2.Bioburden Testing
      • 6.2.2.1.Bioburden Testing Market Estimates And Forecast 2018 - 2030 (USD Million)
    • 6.2.3.Bacterial Endotoxin Testing
      • 6.2.3.1.Bacterial Endotoxin Testing Market Estimates And Forecast 2018 - 2030 (USD Million)

Chapter 7 U.S. Pharmaceutical Sterility Testing Market: Sample Estimates & Trend Analysis

  • 7.1.Definitions And Scope
  • 7.2.U.S. Pharmaceutical Sterility Testing Market Share, 2021 & 2030
    • 7.2.1.Pharmaceuticals
      • 7.2.1.1.Pharmaceuticals Market Estimates And Forecast 2018 - 2030 (USD Million)
    • 7.2.2.Medical Devices
      • 7.2.2.1.Medical Devices Market Estimates And Forecast 2018 - 2030 (USD Million)
    • 7.2.3.Biopharmaceuticals
      • 7.2.3.1.Biopharmaceuticals Market Estimates And Forecast 2018 - 2030 (USD Million)

Chapter 8 U.S. Pharmaceutical Sterility Testing Market: End-Use Estimates & Trend Analysis

  • 8.1.Definitions And Scope
  • 8.2.U.S. Pharmaceutical Sterility Testing Market Share, 2021 & 2030
    • 8.2.1.Compounding Pharmacies
      • 8.2.1.1.Compounding Pharmacies Market Estimates And Forecast 2018 - 2030 (USD Million)
    • 8.2.2.Medical Devices Companies
      • 8.2.2.1.Medical Devices Companies Market Estimates And Forecast 2018 - 2030 (USD Million)
    • 8.2.3.Pharmaceutical Companies
      • 8.2.3.1.Pharmaceutical Companies Market Estimates And Forecast 2018 - 2030 (USD Million)
    • 8.2.4.Others
      • 8.2.4.1.Other Market Estimates And Forecast 2018 - 2030 (USD Million)

Chapter 9 Competitive Analysis

  • 9.1.Recent Developments & Impact Analysis, By Key Market Participant
  • 9.2.Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
  • 9.3.Participant Categorization
    • 9.3.1.Innovators
      • 9.3.1.1.STERIS
      • 9.3.1.2.Boston Analytical
      • 9.3.1.3.Charles River Laboratories
      • 9.3.1.4.SGS SA
  • 9.4.Vendor Landscape
    • 9.4.1.List Of Key Service Providers
    • 9.4.2.Market Differentiators
    • 9.4.3.U.S. Pharmaceutical Sterility Testing Market Share Analysis

Chapter 10 Competitive Landscape

  • 10.1.Company Profiles
    • 10.1.1.SGS SA
      • 10.1.1.1.Company Overview
      • 10.1.1.2.Service Benchmarking
      • 10.1.1.3.Strategic Initiatives
    • 10.1.2.Laboratory Corporation of America Holdings
      • 10.1.2.1.Company Overview
      • 10.1.2.2.Financial Performance
      • 10.1.2.3.Service Benchmarking
      • 10.1.2.4.Strategic Initiatives
    • 10.1.3.Boston Analytical
      • 10.1.3.1.Company Overview
      • 10.1.3.2.Financial Performance
      • 10.1.3.3.Service Benchmarking
      • 10.1.3.4.Strategic Initiatives
    • 10.1.4. Charles River Laboratories
      • 10.1.4.1.Company Overview
      • 10.1.4.2.Financial Performance
      • 10.1.4.3.Service Benchmarking
      • 10.1.4.4.Strategic Initiatives
    • 10.1.5.Pacific Biolabs
      • 10.1.5.1.Company Overview
      • 10.1.5.2.Financial Performance
      • 10.1.5.3.Service Benchmarking
      • 10.1.5.4.Strategic Initiatives
    • 10.1.6.STERIS
      • 10.1.6.1.Company Overview
      • 10.1.6.2.Financial Performance
      • 10.1.6.3.Service Benchmarking
      • 10.1.6.4.Strategic Initiatives
    • 10.1.7. Pace Analytical
      • 10.1.7.1.Company Overview
      • 10.1.7.2.Financial Performance
      • 10.1.7.3.Service Benchmarking
      • 10.1.7.4.Strategic Initiatives
    • 10.1.8.Nelson Laboratories, LLC
      • 10.1.8.1.Company Overview
      • 10.1.8.2.Financial Performance
      • 10.1.8.3.Service Benchmarking
      • 10.1.8.4.Strategic Initiatives
    • 10.1.9.Infinity Laboratories
      • 10.1.9.1.Company Overview
      • 10.1.9.2.Financial Performance
      • 10.1.9.3.Service Benchmarking
      • 10.1.9.4.Strategic Initiatives
    • 10.1.10.Thermo Fisher Scientific, Inc.
      • 10.1.10.1.Company Overview
      • 10.1.10.2.Financial Performance
      • 10.1.10.3.Service Benchmarking
      • 10.1.10.4.Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviations

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Commodity flow analysis
  • Fig. 9 Volume Price Analysis
  • Fig. 10 U.S. pharmaceutical sterility testing market snapshot (2021)
  • Fig. 11 U.S. pharmaceutical sterility testing market segmentation
  • Fig. 12 Market driver relevance analysis (Current & future impact)
  • Fig. 13 Market restraint relevance analysis (Current & future impact)
  • Fig. 14 Penetration & growth prospect mapping
  • Fig. 15 Porter's five forces analysis
  • Fig. 16 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 17 U.S. pharmaceutical sterility testing market type outlook: Segment dashboard
  • Fig. 18 U.S. pharmaceutical sterility testing market: Type movement analysis
  • Fig. 19 In-house U.S. pharmaceutical sterility testing market 2018 - 2030 (USD Million)
  • Fig. 20 Outsourcing U.S. pharmaceutical sterility testing market 2018 - 2030 (USD Million)
  • Fig. 21 U.S. pharmaceutical sterility testing market product type outlook: Segment dashboard
  • Fig. 22 U.S. pharmaceutical sterility testing market: Product type movement analysis
  • Fig. 23 Kits and Reagents market 2018 - 2030 (USD Million)
  • Fig. 24 Instruments market 2018 - 2030 (USD Million)
  • Fig. 25 Service testing market 2018 - 2030 (USD Million)
  • Fig. 26 U.S. pharmaceutical sterility testing market test type outlook: Segment dashboard
  • Fig. 27 U.S. pharmaceutical sterility testing market: Test type movement analysis
  • Fig. 28 Sterility testing market 2018 - 2030 (USD Million)
  • Fig. 29 Membrane Filtration market 2018 - 2030 (USD Million)
  • Fig. 30 Direct Inoculation market 2018 - 2030 (USD Million)
  • Fig. 31 Bioburden testing market 2018 - 2030 (USD Million)
  • Fig. 32 Bacterial endotoxin testing market 2018 - 2030 (USD Million)
  • Fig. 33 Container closure integrity testing market 2018 - 2030 (USD Million)
  • Fig. 34 Rapid micro test market 2018 - 2030 (USD Million)
  • Fig. 35 ATP bioluminescence market 2018 - 2030 (USD Million)
  • Fig. 36 Fluorescent labeling market 2018 - 2030 (USD Million)
  • Fig. 37 Electrical resistance market 2018 - 2030 (USD Million)
  • Fig. 38 Others market 2018 - 2030 (USD Million)
  • Fig. 39 Antimicrobial effectiveness testing market 2018 - 2030 (USD Million)
  • Fig. 40 U.S. pharmaceutical sterility testing market sample outlook: Segment dashboard
  • Fig. 41 U.S. pharmaceutical sterility testing market: Sample movement analysis
  • Fig. 42 Pharmaceuticals market 2018 - 2030 (USD Million)
  • Fig. 43 Medical devices market 2018 - 2030 (USD Million)
  • Fig. 44 Biopharmaceuticals market 2018 - 2030 (USD Million)
  • Fig. 45 U.S. pharmaceutical sterility testing market: Sample movement analysis
  • Fig. 46 U.S. pharmaceutical sterility testing market end-use outlook: Segment dashboard
  • Fig. 47 U.S. pharmaceutical sterility testing market: End-use movement analysis
  • Fig. 48 Compounding Pharmacies market 2018 - 2030 (USD Million)
  • Fig. 49 Medical devices companies market 2018 - 2030 (USD Million)
  • Fig. 50 Pharmaceutical companies market 2018 - 2030 (USD Million)
  • Fig. 51 Others market 2018 - 2030 (USD Million)